1. Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim KS, Jeong YD, Park ES, Kataoka M, Shionoya K, Mifune J, Tsuchimoto K, Ojima S, Azam AH, Nakajima S, Park H, Yoshikawa T, Shimojima M, Kiga K, Iwami S, Maeda K, Suzuki T, Ebihara H, Takahashi Y, *Watashi K. Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. J Infect Dis (in press)
2. Wing PAC, Schmidt NM, Peters R, Erdmann M, Brown R, Wang H, Swadling L, COVIDsortium Investigators, Newman J, Thakur N, Shionoya K, Morgan SB, Hinks TSC, Watashi K, Bailey D, Hansen SB, Davidson AD, Maini MK, McKeating JA. An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity. PLoS Pathog (in press)
3. Nakajima S, Ohashi H, Akazawa D, Torii S, Suzuki R, Fukuhara T, *Watashi K. Antiviral activity of micafungin and its derivatives against SARS-CoV-2 RNA replication. Viruses 15: 452 (2023)
4. Kamisuki S, Shibasaki H, Murakami H, Fujino K, Tsukuda S, Kojima I, Ashikawa K, Kanno K, Ishikawa T, Saito T, Sugawara F, Watashi K, Kuramochi K. Isolation, structural determination, and antiviral activities of metabolites from vanitaracin A-producing Talaromyces sp. J Antibiot 76(2): 75-82 (2023)
5. Saito S, Ohashi H, Nakamura K, Otagaki J, Nishioka K, Nishiuchi K, Nakamura A, Tsurukawa Y, Shibasaki H, Murakami H, Nagane M, Okada M, Kuramochi K, Watashi K, Kamisuki S. Cyclic phthalate esters as liver X receptor antagonists with anti-hepatitis C virus and anti-severe acute respiratory syndrome coronavirus 2 properties. Chem Pharm Bull 70(10): 679-683 (2022)
6. 河岡義裕、大曲貴夫、渡士幸一:新型コロナウイルスの治療薬、インフルエンザ〜その他の呼吸器感染症、23(3): in press、2022
7. 渡士幸一:新型コロナウイルス治療薬、Orga world、34: 16-19、2022
8. Hashimoto R., Tamura T., Watanabe Y., Sakamoto A., Yasuhara N., Ito H., Nakano M., Fuse H., Ohta A., Noda T., Matsumura Y., Nagao M., Yamamoto T., Fukuhara T.*, Takayama K.*, Evaluation of broad anti-coronavirus activity of autophagy-related compounds using human airway organoids, Molecular Pharmaceutics, 2023 Mar 22;20(4):2276-87. *Corresponding author
9. Deguchi S., Kosugi K., Hashimoto R., Sakamoto A., Yamamoto M., Rafal K., Gee P., Negoro R., Noda T., Yamamoto T., Torisawa Y., Nagao M., Takayama K.*, Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips, PNAS Nexus, 2023 Mar 7;2(3):pgad029. *Corresponding author
10. Bodie NM., Hashimoto R., Connolly D., Chu J., Takayama K.*, Uhal BD.*, Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants, Antib Ther. 2023 Jan 20;6(1):59-74. *Corresponding author